Perrigo Company plc logo

Perrigo Company plc

PRGO

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$14.25

+$0.55 · +4.01%

Aug 21, 4:00 PM ET

PRGO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

26

Weakening

Sentiment

56

Mixed

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
IE
CEO
Albert A. Manzone
Listed since
Dec 17, 1991
Employees
8,100

Market position

Day range

Current $14.25

52-week range

Current $14.25

Open
$13.68
Previous close
$13.70
Volume
2.58M
0.84× average
Average volume
3.08M
Average daily volume
Market cap
1.97B USD
Beta
0.54
Market reference 1
50-day average
$11.0864
+28.54% above average
200-day average
$12.216
+16.65% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.37B USD
EV / EBITDA
-6.72×
Earnings yield
-73.93%
Free cash flow yield
7.53%

Profitability & efficiency

Return on equity
-48.56%
Return on assets
-16.70%
Return on invested capital
4.53%

Financial health

Current ratio
2.76×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends43%15%-13%-40%Gross margin, FY2021: 34.22%Gross margin, FY2022: 32.69%Gross margin, FY2023: 36.09%Gross margin, FY2024: 35.27%Gross margin, FY2025: 35.14%Operating margin, FY2021: 9.92%Operating margin, FY2022: 1.77%Operating margin, FY2023: 3.26%Operating margin, FY2024: 2.58%Operating margin, FY2025: 8.07%Net margin, FY2021: -1.66%Net margin, FY2022: -3.16%Net margin, FY2023: -0.27%Net margin, FY2024: -3.93%Net margin, FY2025: -33.51%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 34.22%. Gross margin FY2022 32.69%. Gross margin FY2023 36.09%. Gross margin FY2024 35.27%. Gross margin FY2025 35.14%. Operating margin FY2021 9.92%. Operating margin FY2022 1.77%. Operating margin FY2023 3.26%. Operating margin FY2024 2.58%. Operating margin FY2025 8.07%. Net margin FY2021 -1.66%. Net margin FY2022 -3.16%. Net margin FY2023 -0.27%. Net margin FY2024 -3.93%. Net margin FY2025 -33.51%.

Income trends

Revenue

4.25B USD-2.75%

Operating income

343.3M USD+204.07%

Net income

−1.43B USD-729.69%
Income trends across reported periods5.26B USD2.83B USD398.9M USD−2.03B USDRevenue, FY2021: 4.14B USDRevenue, FY2022: 4.45B USDRevenue, FY2023: 4.66B USDRevenue, FY2024: 4.37B USDRevenue, FY2025: 4.25B USDOperating income, FY2021: 410.4M USDOperating income, FY2022: 78.9M USDOperating income, FY2023: 151.9M USDOperating income, FY2024: 112.9M USDOperating income, FY2025: 343.3M USDNet income, FY2021: −68.9M USDNet income, FY2022: −140.6M USDNet income, FY2023: −12.7M USDNet income, FY2024: −171.8M USDNet income, FY2025: −1.43B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.14B USD. Revenue FY2022 4.45B USD. Revenue FY2023 4.66B USD. Revenue FY2024 4.37B USD. Revenue FY2025 4.25B USD. Operating income FY2021 410.4M USD. Operating income FY2022 78.9M USD. Operating income FY2023 151.9M USD. Operating income FY2024 112.9M USD. Operating income FY2025 343.3M USD. Net income FY2021 −68.9M USD. Net income FY2022 −140.6M USD. Net income FY2023 −12.7M USD. Net income FY2024 −171.8M USD. Net income FY2025 −1.43B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.25B USD4.37B USD4.66B USD4.45B USD4.14B USD
Cost of goods sold2.76B USD2.83B USD2.98B USD3B USD2.72B USD
Gross profit1.49B USD1.54B USD1.68B USD1.46B USD1.42B USD
Research and development95.4M USD112.2M USD122.5M USD123.1M USD122M USD
Selling, general, and administrative526.5M USD1.11B USD1.27B USD1.21B USD1.11B USD
Operating expenses1.15B USD1.43B USD1.53B USD1.38B USD1.01B USD
Interest expense162.5M USD187.8M USD173.8M USD156M USD125M USD
Depreciation and amortization337.5M USD325.9M USD359.5M USD338.6M USD312.2M USD
Operating income343.3M USD112.9M USD151.9M USD78.9M USD410.4M USD
Net income−1.43B USD−171.8M USD−12.7M USD−140.6M USD−68.9M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-10.29
FY2025
Latest fiscal-year revenue
4.25B USD
FY2025 · -2.75% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.93-3.15-7.23-11.31FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend4.71B4.5B4.29B4.09BFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

36 ratings
Strong buy00%
Buy1439%
Hold2158%
Sell13%
Strong sell00%

PRGO news

Corporate actions

Corporate action history

Stock split

Effective Aug 26, 1993

2:1

PRGO peers

ETFs holding PRGO

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research PRGO

research.disclaimer